EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer
- Conditions
- Stage III Lung Cancer AJCC v8EGFR Mutation-Related TumorsStage IIIB Lung Cancer AJCC v8Metastatic Lung Non-Small Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaStage IIIA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8
- Interventions
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Target Recruit Count
- 115
- Registration Number
- NCT05498389
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California, United States
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors.
- Conditions
- Advanced Solid Tumor
- Interventions
- Biological: EMB-09
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05263180
- Locations
- 🇨🇳
FUSCC, Shanghai, China
🇦🇺Peninsula and South Eastern Haematology & Oncology Group, Frankston, Australia
🇦🇺GenesisCareNorthShore, Leonards Hill, Australia
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
- Conditions
- NeoplasmsNeoplasm MetastasisMetastatic Gastrointestinal Carcinoid Tumor
- Interventions
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Target Recruit Count
- 152
- Registration Number
- NCT05176665
- Locations
- 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China
🇨🇳West China Hospital, Sichuan University, Chengdu, China
🇨🇳The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Biological: EMB-06
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT04735575
- Locations
- 🇦🇺
Sunshine Coast Haematology and Oncology Clinic (SCHOC), Buderim, Queensland, Australia
🇦🇺Cabrini Health, Melbourne, Victoria, Australia
🇨🇳Henan Cancer Hospital, Zhengzhou, China
A Study of EMB-02 in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Biological: EMB-02
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Target Recruit Count
- 47
- Registration Number
- NCT04618393
- Locations
- 🇦🇺
Southern Medical Day Care Centre, Wollongong, New South Wales, Australia
🇨🇳HanDan Central Hospital, Handan, Hebei, China
🇺🇸University of Colorado Health Medical Group, Colorado Springs, Colorado, United States
A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors
- Conditions
- NeoplasmsNon-Small-Cell Lung CancerNeoplasm Metastasis
- Interventions
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Target Recruit Count
- 186
- Registration Number
- NCT03797391
- Locations
- 🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇨🇳Shanghai Chest Hosptial, Shanghai, Shanghai, China